| Thomas C Isaacson, MD | |
|
10105 Banburry Cross Dr Ste 250, Las Vegas, NV 89144-6648 | |
| (702) 360-7600 | |
| (702) 363-3814 |
| Full Name | Thomas C Isaacson |
|---|---|
| Gender | Male |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 37 Years |
| Location | 10105 Banburry Cross Dr Ste 250, Las Vegas, Nevada |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1104884311 | NPI | - | NPPES |
| 103715 | Other | UCARE | |
| 51B19IS | Other | MN | MN BCBS |
| 538R81IS | Other | MN | MN BLUE SHIELD |
| 143763100 | Medicaid | MN | |
| 931451029037 | Other | PREFERRED ONE | |
| 0529776 | Medicaid | IA | |
| 0006848 | Other | SD | SD BCBS |
| 25-00471 | Other | SELECTCARE | |
| 60057719 | Medicaid | SD | |
| 25118 | Other | IA | IA BCBS |
| 35614 | Other | HEALTH PARTNERS |
| Facility Name | Location | Facility Type |
|---|---|---|
| Oconomowoc Memorial Hospital | Oconomowoc, WI | Hospital |
| Waukesha Memorial Hospital | Waukesha, WI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Prohealth Medical Group Inc | 3476465188 | 417 |
News Archive
PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has successfully completed a second Phase 1B clinical safety and pilot efficacy study with PMX-60056, a small synthetic molecule designed to reverse heparin and low molecular weight heparin anticoagulants.
Mira DS safely identifies illicit substances and explosives without for direct contact with the material in question, making it an ideal solution.
A modest reduction in consumption of carbohydrate foods may promote loss of deep belly fat, even with little or no change in weight, a new study finds. Presentation of the study results will be Sunday at The Endocrine Society's 93rd Annual Meeting in Boston.
Idera Pharmaceuticals, Inc. today announced the treatment of the first patient in a Phase 2 clinical trial of IMO-3100, the Company's lead Toll-like receptor (TLR) inhibitor for the treatment of autoimmune diseases, in patients with moderate to severe plaque psoriasis.
Metabolic syndrome (MetS) is made up of unhealthy cardiovascular disease (CVD) risk factors including abdominal obesity, high levels of triglycerides, low level of HDL-cholesterol, elevated blood pressure, and elevated fasting glucose level as defined by the American Heart Association/ National Heart, Lung, and Blood Institute (AHA/NHLBI).
› Verified 1 days ago
| Entity Name | Prohealth Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1356322440 PECOS PAC ID: 3476465188 Enrollment ID: O20031103000066 |
News Archive
PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has successfully completed a second Phase 1B clinical safety and pilot efficacy study with PMX-60056, a small synthetic molecule designed to reverse heparin and low molecular weight heparin anticoagulants.
Mira DS safely identifies illicit substances and explosives without for direct contact with the material in question, making it an ideal solution.
A modest reduction in consumption of carbohydrate foods may promote loss of deep belly fat, even with little or no change in weight, a new study finds. Presentation of the study results will be Sunday at The Endocrine Society's 93rd Annual Meeting in Boston.
Idera Pharmaceuticals, Inc. today announced the treatment of the first patient in a Phase 2 clinical trial of IMO-3100, the Company's lead Toll-like receptor (TLR) inhibitor for the treatment of autoimmune diseases, in patients with moderate to severe plaque psoriasis.
Metabolic syndrome (MetS) is made up of unhealthy cardiovascular disease (CVD) risk factors including abdominal obesity, high levels of triglycerides, low level of HDL-cholesterol, elevated blood pressure, and elevated fasting glucose level as defined by the American Heart Association/ National Heart, Lung, and Blood Institute (AHA/NHLBI).
› Verified 1 days ago
| Entity Name | Ascension Medical Group-northern Wisconsin Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1265507537 PECOS PAC ID: 8426960022 Enrollment ID: O20031103000345 |
News Archive
PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has successfully completed a second Phase 1B clinical safety and pilot efficacy study with PMX-60056, a small synthetic molecule designed to reverse heparin and low molecular weight heparin anticoagulants.
Mira DS safely identifies illicit substances and explosives without for direct contact with the material in question, making it an ideal solution.
A modest reduction in consumption of carbohydrate foods may promote loss of deep belly fat, even with little or no change in weight, a new study finds. Presentation of the study results will be Sunday at The Endocrine Society's 93rd Annual Meeting in Boston.
Idera Pharmaceuticals, Inc. today announced the treatment of the first patient in a Phase 2 clinical trial of IMO-3100, the Company's lead Toll-like receptor (TLR) inhibitor for the treatment of autoimmune diseases, in patients with moderate to severe plaque psoriasis.
Metabolic syndrome (MetS) is made up of unhealthy cardiovascular disease (CVD) risk factors including abdominal obesity, high levels of triglycerides, low level of HDL-cholesterol, elevated blood pressure, and elevated fasting glucose level as defined by the American Heart Association/ National Heart, Lung, and Blood Institute (AHA/NHLBI).
› Verified 1 days ago
| Entity Name | Thedacare Incorporated |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1376656959 PECOS PAC ID: 1759294887 Enrollment ID: O20031106000088 |
News Archive
PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has successfully completed a second Phase 1B clinical safety and pilot efficacy study with PMX-60056, a small synthetic molecule designed to reverse heparin and low molecular weight heparin anticoagulants.
Mira DS safely identifies illicit substances and explosives without for direct contact with the material in question, making it an ideal solution.
A modest reduction in consumption of carbohydrate foods may promote loss of deep belly fat, even with little or no change in weight, a new study finds. Presentation of the study results will be Sunday at The Endocrine Society's 93rd Annual Meeting in Boston.
Idera Pharmaceuticals, Inc. today announced the treatment of the first patient in a Phase 2 clinical trial of IMO-3100, the Company's lead Toll-like receptor (TLR) inhibitor for the treatment of autoimmune diseases, in patients with moderate to severe plaque psoriasis.
Metabolic syndrome (MetS) is made up of unhealthy cardiovascular disease (CVD) risk factors including abdominal obesity, high levels of triglycerides, low level of HDL-cholesterol, elevated blood pressure, and elevated fasting glucose level as defined by the American Heart Association/ National Heart, Lung, and Blood Institute (AHA/NHLBI).
› Verified 1 days ago
| Entity Name | Aspirus Stevens Point Hospital & Clinics, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1538112230 PECOS PAC ID: 1850358938 Enrollment ID: O20041210000558 |
News Archive
PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has successfully completed a second Phase 1B clinical safety and pilot efficacy study with PMX-60056, a small synthetic molecule designed to reverse heparin and low molecular weight heparin anticoagulants.
Mira DS safely identifies illicit substances and explosives without for direct contact with the material in question, making it an ideal solution.
A modest reduction in consumption of carbohydrate foods may promote loss of deep belly fat, even with little or no change in weight, a new study finds. Presentation of the study results will be Sunday at The Endocrine Society's 93rd Annual Meeting in Boston.
Idera Pharmaceuticals, Inc. today announced the treatment of the first patient in a Phase 2 clinical trial of IMO-3100, the Company's lead Toll-like receptor (TLR) inhibitor for the treatment of autoimmune diseases, in patients with moderate to severe plaque psoriasis.
Metabolic syndrome (MetS) is made up of unhealthy cardiovascular disease (CVD) risk factors including abdominal obesity, high levels of triglycerides, low level of HDL-cholesterol, elevated blood pressure, and elevated fasting glucose level as defined by the American Heart Association/ National Heart, Lung, and Blood Institute (AHA/NHLBI).
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Thomas C Isaacson, MD Po Box 98978, Las Vegas, NV 89193-8978 Ph: (702) 216-3346 | Thomas C Isaacson, MD 10105 Banburry Cross Dr Ste 250, Las Vegas, NV 89144-6648 Ph: (702) 360-7600 |
News Archive
PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has successfully completed a second Phase 1B clinical safety and pilot efficacy study with PMX-60056, a small synthetic molecule designed to reverse heparin and low molecular weight heparin anticoagulants.
Mira DS safely identifies illicit substances and explosives without for direct contact with the material in question, making it an ideal solution.
A modest reduction in consumption of carbohydrate foods may promote loss of deep belly fat, even with little or no change in weight, a new study finds. Presentation of the study results will be Sunday at The Endocrine Society's 93rd Annual Meeting in Boston.
Idera Pharmaceuticals, Inc. today announced the treatment of the first patient in a Phase 2 clinical trial of IMO-3100, the Company's lead Toll-like receptor (TLR) inhibitor for the treatment of autoimmune diseases, in patients with moderate to severe plaque psoriasis.
Metabolic syndrome (MetS) is made up of unhealthy cardiovascular disease (CVD) risk factors including abdominal obesity, high levels of triglycerides, low level of HDL-cholesterol, elevated blood pressure, and elevated fasting glucose level as defined by the American Heart Association/ National Heart, Lung, and Blood Institute (AHA/NHLBI).
› Verified 1 days ago
Dr. Arshi A. Quadeer, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 2545 S Bruce St Ste 200, Las Vegas, NV 89169 Phone: 702-732-2438 Fax: 702-737-5043 | |
Cherie Lin, D.O. Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 3006 S Maryland Pkwy, Suite 400, Las Vegas, NV 89109 Phone: 702-369-5582 Fax: 702-369-1533 | |
Michael M Lee, MD Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 1800 W Charleston Blvd, Las Vegas, NV 89102 Phone: 702-921-6823 Fax: 702-549-5240 | |
Henry Palangdao Igid, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 653 N Town Center Dr Ste 402, Las Vegas, NV 89144 Phone: 702-243-7200 Fax: 702-243-7235 | |
Ian Adrian Fanoga Frani, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1800 W Charleston Blvd, Las Vegas, NV 89102 Phone: 702-383-2000 Fax: 702-383-3875 | |
Sein Tun, DO Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 620 Shadow Ln, Las Vegas, NV 89106 Phone: 702-388-4000 | |
Berge Jack Dadourian, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 400 S Rampart Blvd, Suite 240, Las Vegas, NV 89145 Phone: 702-906-1100 Fax: 702-906-1110 |